(12) United States Patent
`US 10,039,774 B2
`(10) Patent N0.:
`
`Tabuteau
`(45) Date of Patent:
`*Aug. 7, 2018
`
`U3010039774B2
`
`(54) NERIDRONIC ACID FOR TREATING
`COlVlPLEX REGIONAL PAIN SYNDROME
`
`(71) Applicant: ANTECIP BIOVENTURES II LLC,
`New York, NY (US)
`
`(72)
`
`Inventor: Herriot Tabuteau, New York, NY (US)
`
`.
`( * ) Notice:
`
`(73) ASSignee: ANTECIP BIOVENTURES II LLC,
`New York, NY (US)
`.
`.
`.
`.
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`.
`.
`.
`.
`.
`This patent is subject to a terminal dis—
`claimer.
`
`(21) Appl. No.: 15/782,480
`
`(22) Filed:
`
`Oct-12, 2017
`
`A61K 47/12
`A6]K 45/06
`(52) U.S. Cl.
`CPC
`
`(2006.01)
`(2006.01)
`
`A61K 31/675 (2013.01): A61K 9/0053
`(2013.01); A61K 9/20 (2013.01); A61K 9/2004
`(2013.01); A61K 9/28 (2013.01); A61K 31/663
`(2013.01); A61K 45/06 (2013.01); A61K 47/12
`(2013.01)
`
`(58) Field of Classification Search
`CPC .................................................... A61K 31/633
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4,939,130 A
`5,869,471 A
`
`7/1990 .laeggi et a1.
`2/1999 Hovancik et a1.
`(Continued)
`
`
`
`
`FOReIGN PATeNl DOCUMENTS
`
`(65)
`
`Prior Publication Data
`
`CN
`EP
`
`101259133
`1057488
`
`3/2008
`12/2000
`
`US 2018/0042947 A1
`
`Feb. 15, 2018
`
`Related U.S. Application Data
`(63) Continuation of application No. 15/647,l40, filed on
`.1111. 11‘ 2017 now Pat, NO. 9 820 999 which is a
`continuation—iil—part of application No. a 1 51/357,932,
`filed on Nov. 21. 2016, now Pat. No. 9,707,245,
`which is a continuation-iii—part of application No.
`14/530,556,
`filed on Oct. 31, 2014, which is a
`continuation-in-part of application No. 14/279,229,
`(Continued)
`
`(51)
`
`Int. Cl.
`A61K 31/675
`A61K 9/00
`A61K 31/663
`A61K 9/28
`A61K 9/20
`
`(200601)
`(200901)
`(2006301)
`(2006.01)
`(2006.01)
`
`180—
`
`(Confirmed)
`
`OTHER PUBLICATIONS
`
`18, 2017 First Named
`filed Oct.
`U.S. Appl. No. 15/787,612,
`Invcntor: Harriet Tabutcau Assigncc: Antccip Biovcnturcs II LLC.
`(Continued)
`.
`.
`.
`.
`
`
`Primary Exammer 7 San Mlng R Hui
`
`
`(74) Attorney, Agent, or Firm MaschomBremian
`Laycock Gilmore; Brent A. Johnson; Yuefen Zhou
`
`ABSTRACT
`(57)
`Ostcoclast inhibitors, such as ncridronic acid, in an acid or
`a salt form can be used to treat or alleviate pain or related
`conditions. such as complex regional pain syndrome.
`
`29 Claims, 17 Drawing Sheets
`
`~—.:>——— Vehicle
`
`#7457" Zoledronic acid 18 mg/m 50.
`~
`Zoledronic acid 120 mg/m sq.
`——*—- Zoledronic acid 900 mg/m sq.
`
`E
`
`g
`g
`f”:
`é
`9D.
`g
`‘3
`
`E
`E
`
`160*
`
`140~
`
`1204
`
`100~
`
`80 ~
`
`60
`
`
`l
`
`Dayl
`BL
`
`r
`
`Dayl
`(0511:)
`
`1
`
`Day}
`(1hr)
`
`Dayl
`(3hr)
`
`1
`
`1
`
`1
`
`Day 2
`BL
`
`Day 2
`(1111)
`
`Day 3
`BL
`
`1 Day 3 I
`(1hr)
`
`Griin. Exh. 1002
`PGR for U.S. Patent No. 10,052,338
`
`Grün. Exh. 1002
`PGR for U.S. Patent No. 10,052,338
`
`1
`
`

`

`US 10,039,774 B2
`
`Page 2
`
`Related US. Application Data
`
`filed on May 15, 2014, now Pat. No. 9,034,889, which
`is a continuation of application No. 14/063,979, filed
`on Oct. 25, 2013, now Pat. No. 8,802,658, which is a
`continuation-in-part of application No. 13/894,274,
`filed on May 14, 2013, application No. 15/357,932,
`which is a continuation-in—part of application No.
`PCT/US2015/032739, filed on May 27, 2015, which
`is a continuation of application No. PCT/U32014/
`050427, filed onAug. 8, 2014, which is a continuation
`ofapplication N0. 14/279,24 1, filed on May 15, 2014.
`
`Provisional application No. 62/431,287, filed on Dec.
`7, 2016, provisional application No. 62/378,140, filed
`on Aug. 22, 2016, provisional application No.
`61/646,538, filed on May 14, 2012.
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`(60)
`
`(56)
`
`6,015,801 A
`6,419,955 B1
`6,943,155 B2
`7,658,939 B2
`7,704,977 B2
`8,053,429 B2
`8,119,159 B2
`8,323,689 B2
`8,323,690 B2
`8,399,023 B2
`8,772,267 B2
`8,802,658 B2
`8,822,436 B1
`8,828,431 B2
`8,835,650 B1
`8,859,530 B2
`8,865,757 B1
`8,883,201 B2
`8,883,203 B2
`8,901,161 B1
`8,901,162 B1
`8,933,057 B2
`8,962,599 B1
`9,006,279 B1
`9,034,889 B2
`9,079,927 B1
`9,149,487 B2
`9,169,279 B2
`9,205,045 B1
`9,211,257 B2
`9,216,153 B2
`9,216,168 B1
`9,265,778 B2
`9,278,106 B2
`9,283,239 B2
`9,289,384 B2
`9,289,385 B2
`9,289,441 B2
`9,290,575 B2
`9,301,964 B2
`9,408,860 B2
`9,408,861 B2
`9,408,862 B2
`9,427,403 B2
`9,511,081 B2
`9,517,242 B2
`9,522,157 B2
`9,539,268 B2
`9,585,901 B2
`9,585,902 B2
`9,610,300 B2
`9,616,077 B2
`9,616,078 B2
`9,623,036 B2
`
`1/2000 Daifotis
`7/2002 Gabe] et all
`9/2005 Lichtenbergei‘
`2/2010 Oshlack et a1.
`4/2010 Leonard
`11/2011 Cumming et al.
`2/2012 Cumming et a1.
`12/2012 Cumming et al.
`12/2012 Cumming ct a1.
`3/2013 llanna et all
`7/2014 Paapagallo
`8/2014 TaJu eau
`9/2014 TaJu eau
`9/2014 Cumming et al.
`9/2014 Taaueau
`10/2014 Desai
`10/2014 Taaucau
`11/2014 Leonard
`11/2014 Lennard
`12/2014 TaJu eau
`12/2014 TaJu eau
`1/2015 Hanna et a1.
`2/2015 Taaueau
`4/2015 Taaueau
`5/2015 Taaueau
`7/2015 Taaucau
`10/2015 Tam eau
`10/2015 Hanna et al.
`12/2015 TaJu eau
`12/2015 Taaueau
`12/2015 Taaueau
`12/2015 Taaueau
`2/2016 Taaueau
`3/2016 Taaucau
`3/2016 'l'ajueau
`3/2016 Tam eau
`3/2016 TaJu eau
`3/2016 TaJu eau
`3/2016 Taaueau
`4/2016 Taaueau
`8/2016 Taaueau
`8/2016 Taaueau
`8/2016 Taaucau
`8/2016 Tam eau
`12/2016 Taju eau
`12/2016 TaJu eau
`12/2016 Taaueau
`1/2017 Taaueau
`3/2017 Taaueau
`3/2017 Taaueau
`4/2017 Taaucau
`4/2017 'l'ajueau
`4/2017 Tam eau
`4/2017 TaJu eau
`
`
`
`
`
`9,623,037
`9,623,038
`9,655,908
`9,662,343
`9,669,040
`9,675,626
`9,694,022
`9,694,023
`9,700,570
`9,707,245
`9,707,247
`9,717,747
`9,770,457
`9,782,421
`9,789,128
`9,795,622
`9,820,999
`9,827,192
`9,827,256
`9,844,559
`9,855,213
`9,861,648
`9,867,839
`9,867,840
`9,877,977
`9,884,069
`9,925,203
`9,931,352
`9,943,531
`9,949,993
`9,956,234
`9,956,237
`9,956,238
`2004/0063670
`200 5/0026871
`2005/0054616
`200 5/0260262
`2006/0068010
`2007/0134319
`2009/0281064
`20
`0/0121040
`20
`0/0215743
`20
`1/0028435
`20
`1/0098252
`20
`2/0190647
`20
`3/0035315
`20
`3/0274282
`20
`3/0303485
`20
`3/0303486
`20
`3/0303487
`20
`3/0303488
`20
`4/0051669
`20
`4/0051718
`20
`4/0107345
`20
`4/024 9107
`20
`4/021 9108
`20
`4/021 9109
`20
`4/0249110
`2014/0249111
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`20
`
` 4/02491 12
`
`
`4/0249113
`4/0249317
`4/0256683
`4/0329773
`4/031 8916
`4/034 9974
`5/0051175
`5/0057250
`5/0133403
`5/014 1373
`5/014 1374
`5/014 8312
`5/0157564
`5/0164929
`5/0216884
`5/0344505
`5/0361179
`6/0038517
`6/0095871
`
`"abuteau
`4/2017
`"abuteau
`4/2017
`"abuteau
`5/2017
`Tabuteau
`5/2017
`"abuteau
`6/2017
`"abuteau
`6/2017
`7/2017
`"abuteau
`7/2017 '
`'abuteau
`7/2017
`"abuteau
`7/2017
`"abuteau
`7/2017
`"abuteau
`8/2017
`Tabuteau et al.
`9/2017
`Tabuteau
`10/2017
`"abuteau
`10/2017
`"abuteau
`10/2017
`Tabutcau
`11/2017 '
`'abuteau
`11/2017
`"abuteau
`11/2017
`"abuteau
`12/2017
`"abuteau
`1/2018
`Tabuteau
`1/2018
`"abuteau
`1/2018
`"abuteau
`1/2018
`"abuteau
`1/2018 '
`'abuteau
`2/2018
`"abuteau
`3/2018
`"abuteau
`4/2018
`"abuteau
`4/2018
`Tabuteau
`4/2018
`Tabuteau
`5/2018
`"abuteau
`5/2018
`"abuteau
`5/2018
`Tabutcau
`4/2004
`FOX et a1.
`2/2005
`Flashnei'-Barak et al.
`3/2005
`Aronhiine et 31.
`Dansereau
`11/2005
`3/2006
`Turner et a1.
`6/2007
`Zannou et ai.
`11/2009
`Ahmed et a1.
`5/2010
`Nakazawa
`8/2010
`Leonard
`2/2011
`llanna et all
`4/2011
`Pappagallo
`7/2012
`Hanna et al.
`2/2013
`Hanna et al.
`10/2013
`Tabuteau
`11/2013
`"abuteau
`11/2013
`"abuteau
`11/2013
`Tabutcau
`1 1/2013
`"abuteau
`2/2014
`"abuteau
`2/2014
`"abuteau
`4/2014
`"abuteau
`9/2014
`Tabuteau
`9/2014
`"abuteau
`9/2014
`"abuteau
`9/2014
`Tabutcau
`9/2014 '
`'abuteau
`9/2014
`"abuteau
`9/2014
`"abuteau
`9/2014
`"abuteau
`9/2014
`Tabuteau
`11/2014
`Tabuteau
`11/2014
`"abuteau
`11/2014
`"abuteau
`2/2015
`Tabutcau
`2/2015
`"abuteau
`5/2015
`"abuteau
`5/2015
`Tabuteau
`5/2015
`"abuteau
`5/2015
`"abuteau
`6/2015
`"abuteau
`6/2015
`"abuteau
`8/2015
`'
`'abuteau
`12/2015
`"abuteau
`12/2015
`"abuteau
`2/2016
`Tabutcau
`4/2016
`"abuteau
`
`
`
`
`
`
`>>>>>>>>>2’>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
`
`2
`
`

`

`US 10,039,774 B2
`
`Page 3
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`2016/0095872 A1
`2016/0113950 A1
`2016/0151398 A1
`2016/0158254 A1
`2016/0158255 A1
`2016/0158256 A1
`201(/0166589 A1
`2016/0166590 A1
`2016/0175333 A1
`2016/0199394 A1
`2016/0199395 A1
`2016/0206636 A1
`2016/0235772 A1
`2016/0263134 A1
`2016/0296539 A1
`2016/0324882 A1
`2016/0331679 A1
`2016/0331766 A1
`2016/0331767 A1
`2016/0331768 A1
`2017/0042914 A1
`2017/0049791 A1
`2017/0056425 A1
`2017/0056426 A1
`2017/0055427 A1
`2017/0065620 A1
`2017/0065621 A1
`201760065622 A1
`2017/0065624 A1
`20170065623 A1
`2017/0065625 A1
`2017/0071958 A1
`2017/0071950 A1
`2017/0079995 A1
`2017/0079996 A1
`2017/0079997 A1
`2017/0079998 A1
`2017/0087168 A1
`2017’:0087169 A1
`20110095486 A]
`2017/0095487 A1
`2017/0095488 A1
`2017/0100416 A1
`2017/0100417 A1
`2017/0119301 A1
`2017/0128470 A1
`2017/0128472 A1
`2017/0136046 A1
`2017/0143747 A1
`2017’:0157039 A1
`20170157152 A1
`2017/0157153 A1
`2017/0172917 A1
`2017,,0173054 A1
`2017/0182072 A1
`2017/0209469 A1
`2017/0216324 A1
`2017/0224710 A1
`2017/0232018 A1
`2017/0252299 A1
`2017/0252361 A1
`2017/0260144 A1
`2017/0286209 A1
`2017/0231654 A1
`2017/0281655 A1
`2017/0281656 A1
`201170304331 A1
`2018/0000848 A1
`2018/0015110 A1
`2018/0015112 A1
`2018/0021358 A1
`2018/0028544 A1
`2018/0110789 A1
`2018/0133232 A1
`2018/0140621 A1
`
`4/2016 Ta3u eau
`4/2016 Ta3u eau
`6/2016 Ta 311 eau
`6/2016 Taau eau
`6/2016 Taau eau
`6/2016 Tam eau
`6/2016 Ta :lll eau
`15/2016 TaJu eau
`6/2016 Ta3u eau
`7/2016 Ta3u eau
`7/2016 Ta3u eau
`7/2016 Taau eau
`55/2016 Taau eau
`9/2016 'l'aju eau
`10/2016 Tam eau
`11/2016 Tam eau
`11/2016 TaJu eau
`11/2016 Ta3u eau
`11/2016 TaJu eau
`11/2019 TM! eau
`2/,201./, Tagu eau
`“01’ Tm“ ca“
`3/2017 Taau eau
`3/2017 Ta 3“ eau
`3/2017 Tam eau
`3/2017 TaJu eau
`3/2017 Taau eau
`3/:2012 Ta3u eau
`3/201 / Taau eau
`36201; Tame“
`3/2017 '1'a3u eau
`3/2017 Tam eau
`3/2017 Ta 311 eau
`3/2017 Taju eau
`3/2017 Ta3u eau
`3/2017 Ta3u eau
`3/2017 T513“ eau
`3/2012 7““ ea“
`34201,],
`1a3u eau
`4620‘; Tm“ ea“
`4/201/ Ta :lll eau
`4/2017 TaJu eau
`4/2017 Ta3u eau
`41/2017 TaJu eau
`5/2017 Ta3u eau
`5/2017 Taju eau
`5/2017 TaJu eau
`5/2017 'l'aju eau
`55/2017 Tam eau
`6/:ZOIZ Tagu eau
`66201; TD“ ca“
`6/201/ Ta3u eau
`6/2017 TaJu eau
`6/2017 TaJu eau
`6/2017 TaJu eau
`7/2017 '1'a3u eau
`8/2017 Tam eau
`8/2017 Ta 311 eau
`8/2017 TaJu eau
`9/2017 T213“ eau
`9/2017 TaJu eau
`9/201: TaJu eau
`9/,201’ Tagu eau
`“”2017 “31‘0"“
`10/2017 '1'a3u eau
`10/2017 Ta 3“ eau
`[0/2017 Tagu eau
`1/2018 TaJu eau
`1/2018 Taju eau
`1/2018 TaJu eau
`1/2018 Tam eau
`2/2018 Taju eau
`4/2018 TaJu eau
`5/2018 '1'a3u eau
`5/2018 TaJu eau
`
`
`
`
`
`
`
`
`
`FOR 7 IGN PAT 3N1 DOCUIVIENTS
`1999015155
`4/1999
`2000028954
`5/2000
`2002043738
`/2002
`2002087555
`11/2002
`2003075741
`9/2003
`2004035061
`4/2004
`2005063218
`/2005
`2005072747
`/2005
`2005107751
`11/2005
`2005115331
`12/2005
`2005115406
`12/2005
`2006102117
`/2006
`2011014781
`2/2011
`2012071517
`5/2012
`2013173330
`11/2013
`
`WO
`WO
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`OTHER PUBLICATIONS
`
`
`
`filed Mar. 18, 2016 First Named
`U.S. Appl. No. 15/074,367,
`Inventor: Herriot "abuteau Assignee: Antecip Bioventures II LLC.
`U.S. Appl. No. 15/074,380,
`filed Mar. 18, 2016 First Named
`Inventor: Herriot '
`'abuteau Assignee: Antecip Bioventures 11 LLC.
`U s A 1 N 1'/083 105
`fil d Mar 28 2016 F'
`t N
`d
`‘
`'
`PP'
`_°‘ 3
`,
`.
`_ e
`'
`,
`.
`_
`”S we
`Inventor Herrlot ' abuteau Ass1gnee: AnteClp Bloventures II LLC .
`U.S. Appl. No.
`5/136,092,
`filed Apr. 22. 2016 First Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`Us. Appl. No. 15/164,651,
`filed May 25, 2016 First Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`.
`.
`.
`.
`11s Appl.No. 15/188,725, filed Jun. 21, 2016 First Named Inven-
`tor: Herrlot Tabuteau Ass1g11ee: Ante01p Bloventures II LLC.
`US. Appl. No. 15/211,827, filed Jul 15, 2016 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/217,752, filed Jul. 22, 2016 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`U.S. Appl. No. 15/217,773, filed Jul. 22, 2016 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`Us. Appl. No. 15/223,487, filed Jul, 29. 2016 First Named Inven-
`tor: Ilerriot Tabuteau Assignee: Antecip Bioventures II I.I.C.
`Us. Appl. No. 15/223,548, filed Jul, 29, 2016 First Named Inven-
`.
`.
`.
`.
`,,
`tor: Herrlot Tabuteau Ass1gnec: Ante01p Bloventures II LLC.
`Turner-Stokes et al., Complex Regional Pain Syndrome in Adults:
`Concise Guidance, Clinical Medicine. 11(6), 596—600. Dec. 2011.
`US Food and Drllg Administration, CRPS Orphan Drug Designa-
`tion for Zoledronic Acid,
`1 pg, May 6, 2013, available at http://
`wwwaccessdatafda.gov/scripts/opdlisting/oopd’OOPDiResults72.
`efm?Index7NLunbere374112.
`Van Beek et a1.. Binding and Antiresorptive Properties of Hetero—
`cycle-Containing Bisphosphonate Analogs: Structure-Activity
`Relationships, Bone, 23(5), 437—442, Nov. 1998,
`V Oflel et al
`Influence of C 'clic Intravenous Pamidronatc on
`fin.
`"
`:
`.1
`3
`.
`1
`.
`.
`Promflammatory Monocytlc Cytokme Profiles and Bone Dens1ty ln
`RheumatOld Arthrltls Treated With Low Dose Prednlsolone and
`Methrotrexate, Clinical and Experimental Rheumatology, 19(1),
`1340, Jan. 2001~
`Varenna et al., Intravenous Clodronate in the Treatment of Reflex
`Sympathetic Dystrophy Syndrome. A Randomized, Double Blind,
`Placebo Controlled Study. The Journal of Rheumatology. 27(6),
`1477.143], Jun 2000‘
`Varenna et al., Treatment of Complex Regional Pain Syndrome
`Type I with Neridronate: A Randomized, Double-Blind. Placebo-
`C t
`lled Stud , Rheleatolo
`534—542 Nov 2012
`0“ I"
`V.”
`.
`EV:
`:
`:
`7'
`Walker et al., Disease Modifying and _Antl-Noc1ceptlve Effects of
`the Blsphosphonate, 7.oledronlc ACId In a Model of Bone Cancer
`Pain. Pain, 100(3). 219-229, Dec 2002
`Yanow et al., Complex Regional Pain Syndrome (CRPS/RSD) and
`Neuropathie Pain: Role of Intravenous Bisphosphonates as Anal-
`gesics, The Scientific World Journal, 8, 229-236, Feb. 2008.
`7aspel et al., Treatment of Farly Stage CRPS 17C01tisone
`('Methylprednisolone) Versus Bisphosphonate (Zoledronic Acid),
`German Congress of Orthopedics and Traumatology, Berlin, DE,
`Oct, 24-27, 2007.
`
`3
`
`

`

`US 10,039,774 B2
`
`Page 4
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Zhang et al., Modic Changes: A Systematic Review of the Litera-
`ture, Furopean Spine Journal, [7(10), 1289-1299, Oct. 2008.
`Altman et al., Low Back Pain in Paget‘s Disease of Bone, Clinical
`Orthopedic and Related Research, 217, 152-161, Apr. 1987.
`Hendren et al., A Review of the Diiferences Between Normal and
`Osteoarthritis Artieular Cartilage in Human Knee and Ankle Joints,
`The Foot, 19(3), 171-176, Sep. 2009.
`McHugh et al., MER—101 Tablets: A Pilot Bioavailability Study of
`a Novel Oral Formulation of Zoledronic Acic, Molecular Cancer
`Therapeutics, Nov. 2007; B194.
`US. Appl. No. 15/246,325,
`filed Aug. 24, 2016 :irst Named
`Inven or: Herrio Tabuteau Assignee: An ecip 3ioventures II LLC.
`US. Appl. No. 15/335,381,
`filed Oct. 26, 2016 :irst Named
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No. 15/347.696. filed Nov. 9. 2016 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures I LLC.
`US. Appl. No. 15/348,808,
`filed Nov.
`0, 2016 :irst Namec
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No.
`[fl/348,842,
`filed Nov.
`0, 2016 7irst Namec
`Inven or: Herrio Tabuteau Assignee: An ecip 3ioventures II LLC.
`US. Appl. No. 15/349,926,
`filed Nov.
`1, 2016 :irst Named
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No. 15/352,461,
`filed Nov.
`5, 2016 :irst Namec
`Inven or: IIerrio Tabuteau Assignee: An ecip 3ioventures II I,I,C.
`US. Appl. No. 15/353,550,
`filed Nov.
`6, 2016 :irst Namec
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No. 15/354,862,
`filed Nov.
`7, 2016 just Namec
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No. 15/354,908,
`filed Nov.
`7, 2016 *irst Namec
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No.
`Iii/356,434,
`filed Nov.
`8, 2016 :irst Namec
`Inven or: Herrio Tabuteau Assignee: An ecip 3ioventures II LLC.
`US. Appl. No. 15/357,769,
`filed Nov. 21, 2016 :irst Nainec
`Inven or: Herrio Tabuteau Assignee: An ecip 3ioventures II LLC.
`US. Appl. No. 15/357,932,
`filed Nov. 21, 2016 :irst Namec
`Inven or: IIerrio Tabuteau Assignee: An ecip 3ioventures II I,I,C.
`US. Appl. No. 15/360.886,
`filed Nov. 23. 2016 :irst Namec
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No. 15/364,117,
`filed Nov. 29, 2016 :irst Named
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No. 15/365,748,
`filed Nov. 30, 2016 :irst Namec
`Inven or: Herrio Tabuteau Assignee: An ecip Bioventures II LLC.
`US. Appl. No. 15/367,048, filed Dec. 1. 2016 First Named Inventor:
`IIerriot Tabuteau Assignee: Antecip Bioventures II II,C.
`US. Appl. No. 15/368.355, filed Dec. 2, 2016 First Named Inventor:
`Hcrriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/37l,052, filed Dec. 6, 2016 First Named Inventor:
`Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No.
`[fl/377,907,
`filed Dec.
`13, 2016 First Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/378,939,
`filed Dec. 14, 2016 First Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/380.824,
`filed Dec. 15. 2016 First Named
`Inventor: IIerriot Tabuteau Assignee: Antecip Bioventures II I,I,C.
`US. Appl. No. 15/384,125,
`filed Dec. 19, 2016 First Named
`Inventor: Hcrriot Tabuteau Assignee: Antecip Bioventures II LLC.
`Marmo et al., Experimental analysis of certain pharmacodynamic
`features of ketoprofen lysine, Archive for Medical Sciences, 137.
`387-395, 1980. (English Translation).
`to Treat Painful
`Varenna, Elfieacy Study of Neridronate
`Osteoarthritis of the Knee With Bone Marrow Lesions, ClinicaITri-
`als.gov, 3 pgs.,
`last accessed on Mar. 13, 2013, available at:
`https://clinicaltrials.gov/ct2/show/NCT01803360.
`Grfinenthal GMBII, Efficacy and Safety ot‘Intraveneous Neridronic
`Acid in CRPS-I, ClinicalTrials.gov, 6 pgs., last accessed on Nov. 11,
`2016,
`available
`at:
`https ://clinicaltrials . gov/ct2/show/
`NCT02402530.
`
`US Food and Drug Administration, Pharmacology Review of
`ZOMETA®, 261 pgs.. Nov. 2001, available at: http://wwwac—
`cessdata.fdagov/drugsatfdaidoc s/nda/200 l /2 l -22377,ometa.cfm.
`US Food and Drug Administration, Severe Pain with Osteoporosis
`Drugs; FDA patient safety news: Show #73,
`1 pg, Mar. 2008,
`available
`at:
`http://WWW.filagov/downloat s/Sal‘ety/
`FDAPatientSafetyNews/L'CM4 17867 .pdf.
`US. App . No. 13/894,244,
`filed May 14, 20 3 Firs Named
`Inventor: F erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No. 13/894,252,
`filed May 14, 20 3 Firs Named
`Inventor: I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No. 13/894,262.
`filed May 14. 20 3 Firs Named
`Inventor I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC .
`US. App . No. 13/894,274,
`filed May 14, 20 3 Firs Named
`Inventor: Ir erriot '
`'abuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No.
`4/063,979,
`filed Oct. 25, 2013 First Named
`Inventor: F erriot "abuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No. 14/106,291,
`filed Dec. 13, 20 3 Firs Named
`Inventor: F erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No. 14/279,I96,
`filed May 15, 20 4 Firs Named
`Inventor: I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No. 14/279.206.
`filed May 15. 20 4 Firs Named
`Inventor I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC .
`US. App . No. 14/279,213,
`filed May 15, 20 4 Firs Named
`Inventor: Ir erriot '
`'abuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No.
`l4/279,222,
`filed May 15, 20 4 Firs Named
`Inventor: F erriot "abuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No.
`l4/279,226,
`filed May 15, 20 4 Firs Named
`Inventor: F erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No. 14/279,229,
`filed May 15, 20 4 Firs Named
`Inventor: I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No.
`I4/279,232,
`filed May 15, 20 4 Firs Named
`Inventor I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC .
`US. App . No. 14/279,236,
`filed May 15, 20 4 Firs Named
`Inventor: Ir erriot '
`'abuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No.
`l4/279,24I,
`filed May 15, 20 4 Firs Named
`Inventor: F erriot "abuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No.
`l4/288,24I,
`filed May 27, 20 4 Firs Named
`Inventor: F erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App. No. 14/288,713,
`filed May 28, 20 4 Firs Named
`Inventor: I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC.
`US. App . No.
`I4/288,7I6,
`filed May 28, 20 4 Firs Named
`Inventor I erriot Tabuteau Assignee: Antecip Bioven ures
`SLC .
`US. App . No. 14/288,720,
`filed May 28, 20 4 Firs Named
`Inventor: Ir erriot '
`'abuteau Assignee: Antecip Bioven ures
`SLC.
`US. Appl. No. 14/310,811, filed Jun. 20, 2014 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. I4/336,642, filed Jul. 21, 2014 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. I4/446,184, filed Jul. 29, 2014 First
`amed Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No.
`I4/456,939,
`filed Aug. 11, 2014 First Named
`Inventor Herriot Tabuteau Assignee: Antecip Bioven ures II LLC .
`US. Appl. No. 14/457,659.
`filed Aug. 12, 2014 First Named
`Inventor: Herriot '
`'abuteau Assignee: Antecip Bioven ures II LLC.
`US. Appl. No. 14/481,097, filed Sep. 9, 2014 First Named Inventor:
`Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No
`4/530,556,
`filed Oct. 31, 2014 First Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioven ures II LLC.
`US. Appl. No. I4/536,526, filed Nov. 7, 2014 First
`amed Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No.
`I4/538,709,
`filed Nov. 11, 2014 First Named
`Inventor Herriot Tabuteau Assignee: Antecip Bioven Lu‘es II LLC.
`US. Appl. No. 14/540,333.
`filed Nov. 13, 2014 First Named
`Inventor: Herriot '
`'abuteau Assignee: Antecip Bioven ures II LLC.
`US. Appl. No. 14/604,524, filed Jan. 23. 2015 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. I4/605,822, filed Jan. 26, 2015 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. I4/607,947, filed Jan. 28. 2015 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. I4/607,985, filed Jan. 28. 2015 First Named Inven—
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`4
`
`

`

`US 10,039,774 B2
`Page 5
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`
`
`US. Appl. No. 14/608,855. filed Jan. 29, 2015 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures I TIC.
`US. Appl. No. 14/625,457,
`filed Feb. 18, 2015 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 14/635.857, filed Mar. 2, 2015 First Named Inventor:
`Herriot 'I'abuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 14/639,013,
`filed Mar. 13, 2015 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 14./686,551,
`filed Apr. 14, 2015 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No:
`l4/967,224,
`filed Dec:
`11, 2015 7irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 14/967,234,
`filed Dec. 11, 2015 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 14/968,514,
`filed Dec. 14, 2015 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II I,I,C.
`US. Appl. No. 15/009,712. filed Jan. 28, 2016 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures I LLC.
`US.App1.No. 15/014,994, filed Feb. 3, 2016 First Named Inventor:
`Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No: 15./042,017,
`filed Feb.
`11, 2016 7irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/043,141,
`filed Feb. 12, 2016 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/043,281,
`filed Feb. 12, 2016 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II I,I,C.
`US. Appl. No. 15/043,419,
`filed Feb. 12, 2016 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/055,386,
`filed Feb 26, 2016 :irst Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`Carbonare et al., Safety and Tolerability of 7,oledronic Acid and
`Other Bisphosphonates
`in Osteoporosis Management, Drug,
`Healthcare & Patient Safety, 2, 121-137, Jan. 2010.
`Pazianas et al., Eliminating the Need for Fasting with Oral Admin-
`istration of Bisphosphonates. Therapeutics & Clinical Risk Man-
`agement, 9, 395-402, 2013:
`WHO Expert Committee on Specifications for Pharmaceutical
`Preparations, Good Manufacturing Practices for Pharmaceutical
`Products: Main Principles, Annex 2, Forty-Eighth Report, WHO
`Technical Report series. 986. 77-135. 2014.
`Anngst. Absorption Enhancers: Applications and Advances, The
`AAPS Journal, 14(1), 10-18. Mar. 2012.
`Auxilium Pharmaceuticals Corporation, Testim® Drug Label, Aug.
`2013.
`Losina et a1.. Lifetime Risk and Age at Diagnosis of Symptomatic
`Knee Osteoarthritis in the US, Arthritis Care & Research, 65(5),
`703-711, May 2013.
`Harden et al., The Osteoarthritis Knee Model: Psychophysical
`Characteristics and Pumtive Outcomes, The Journal of Pain, 14(3):
`281-289. Mar. 2013.
`Spector, Bisphosphonates: Potential Therapeutic Agents for Disease
`Modification in Osteoarthritis, Aging Clinical & Experimental
`Research, 15(5), 413-418, Oct. 2003.
`Spector et al., Effect of Risedronate on Joint Structure and Symp-
`toms of Knee Osteoarthritis: Results of the BRISK Randomized.
`Controlled Trial [ISRCTN01928173], Arthritis Reserch & Therapy,
`7(3), R625, Mar. 2005.
`Carbone et al., The Relationship of Antiresorptive Drug Use to
`Structural Findings and Symptoms of Knee Osteoarthritis, Arthritis
`& Rheumatism. 50(11). 3516-3525. Nov. 2004.
`Fujita
`et
`al., Comparison of
`the Analgesic Effects of
`Bisphosphonates: Etidronate, Alendronate and Risedronate by
`Electroalgometry Utilizing the Fall of Skin Impedance, Journal of
`Bone & Mineral Metabolism, 27(2), 234-239, Mar. 2009.
`Piscitelli et a1.. Painful Prosthesis: Approaching the Patient with
`Persistent Pain Following Total Hip and Knee Arthroplasty, Clinical
`Cases in Mineral & Bone Metabolism, 10(2), 97-110. May 2013.
`Riedel, Nociception, Pain, and Antinociception: Current Concepts,
`Zeitsehrift fur Rheumatologie, 60(6), 404-415. Dec. 2001.
`
`
`
`Chen et al., Osteoalthritis: Toward a Comprehensive Understanding
`of Pathological Mechanism. Bone Research. 5, 16044. Jan. 2017.
`Harden et al., Prospective Examination of Pain-Related and Psy-
`chological Predictors of CRPS-Like Phenomena Following Total
`Knee Arthroplasty: A Preliminary Study, PAIN, 106(3), 393-400,
`Dec. 2003.
`Harden et a1.. Development of a Severity Score for CRPS, PAIN.
`151(3), 870-876, Dec. 2010.
`Bruehl
`et al., Associations Between KCNJ6 (GIRK2) Gene
`Polymorphisms and Pain-Related Phenotypes, PAIN, 154(12),
`2853-2859, Dec. 2013.
`Rowe et al., Handbook of Pharmaceutical Excipients. 6th edition.
`Pharmaceutical Press, London, England, 285, 2009.
`Banker & Rhodes, Modern Pharmaceutics, second edition, Drugs
`and Pharmaceutical Sciences, vol. 40, 1-142, 1990 (Chapter 3:
`Pharmacokineties).
`filed May 18. 2017 First Named
`US. Appl. No. 15/599.319.
`Inventor Herriot Tabuteau Assignee: Antecip Bioventures II LLC .
`US. Appl. No. 15/604,394,
`filed May 24, 2017 First Named
`Inventor: Herriot '
`'abuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/605,730,
`filed May 25, 2017 First Named
`Inventor: Herriot "abuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/623,274, filed Jun. 14. 2017 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/624,428, filed Jun. 15. 2017 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/624,471, filed Jun. 15. 2017 First Named Inven—
`tor: Herriot Tabuteau Assignee: Antecip Bioventtrres II LLC.
`US. Appl. No. 15/647,140, filed Jul. 11, 2017 First Named Inven-
`tor: Herriot 'I'abuteau Assignee: Antecip Bioventures II LLC.
`Expert Declaration of Dr. Socrates Papapoulos, paragraphs 40-46,
`Apr. 2017.
`Grlmenfha/ (iMBH v. Antecip Bioventures IILLC, Case PGR2017-
`00008, U.S. Pat. No. 9,238,239, Patent Owner‘s Preliminary
`Response, p. 35, Apr. 2017.
`Grzmemhal GIVIBH v. Antecip Bioventures II LLC, Case PGR2017-
`00008, US. Pat. No. 9,238,239, Decision, Institution of Post—Grant
`Review, pp. 29-30, Jul. 2017.
`US. Appl. No. 15/672,126, filed Aug. 8, 2017 First Named Inven—
`tor: Herriot 'I'abuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/672,147, filed Aug. 8, 2017 First Named Inven-
`tor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`Guermazi et a1.. Different Thresholds for Detecting Osteophytes and
`Joint Space Narrowing Exist Between the Site Investigators and the
`Centralized Reader in a Multicenter Knee Osteoarthritis Studyi
`Data
`from the Osteoarthritis
`Initiative, Skeletal Radiology,
`41(2),179-86, Feb. 2012.
`Jimenez-Boj et al., Interaction Between Synovial Inflammatory
`Tissue and Bone Marrow in Rheumatoid Arthritis. The Journal of
`Immunology, 175(4). 2579-2588, Aug. 2005.
`Wolfe et al., Assessment of Pain in Rheumatoid Arthritis: Minimal
`Clinically Significant Difference. Predictors, and the Effect of
`Anti-tumor Necrosis Factor Therapy. The Journal of Rheumatology,
`34(8),1674-1683, Aug. 2007.
`US. Appl. No. 15./697,211, filed Sep. 6,2017 First Named Inventor:
`Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No. 15/697,267, filed Sep. 6, 2017 First Named Inventor:
`Herriot Tabuteau Assignee: Antecip Bioventures II LLC
`US. Appl. No.
`5/702.616,
`filed Sep. 12. 2017 First Named
`Inventor: Herriot '
`'abuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No.
`5/703,891,
`filed Sep. 13. 2017 First Named
`Inventor: Herriot "abuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No
`5/707,238,
`filed Sep. 18. 2017 First Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No.
`5/7 7.673,
`filed Sep. 18. 2017 First I\amed
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`US. Appl. No.
`5/710,759,
`filed Sep. 20. 2017 First Named
`Inventor Herriot Tabuteau Assignee: Antecip BioventLu‘es II LLC.
`Mackey et al., Pharmacologic Therapies for Complex Regional Pain
`Syndrome, Curren Pain and Headache Reports. 11 (I), 38-43, Mar.
`2007.
`filed Sep. 26. 2017 First Named
`5/716,334,
`US. Appl. No.
`Inventor Herriot Tabuteau Assignee: Antecip BioventLu‘es II LLC.
`
`
`
`
`
`5
`
`

`

`US 10,039,774 B2
`
`Page 6
`
`(56)
`
`References Cited
`OTHER PUBLICATIONS
`
`Grl'inenthal GMBH, Petition for P0 st Grant Review of US. Pat. No.
`9,539,268, Oct. 10, 2017.
`filed Oct. 12, 2017 First Named
`US. Appl. No. 15/782,480,
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventtu‘es II LLC.
`U.S. Appl. No. 15/787,612,
`filed Oct. 18, 2017 First Named
`Inventor: Herriot Tabuteau Assignee: Antecip Bioventures II LLC.
`Grl'inenthal GMBH, Declaration of Stephen Bruehl, for Petition for
`Post Grant Review of US. Pat. No. 9,539,268, Oct. 10, 2017.
`Grtinenthal GMBH, Declaration of Clive G. Wilson, for Petition for
`Post Grant Review of US. Pat. No. 9,539,268, Oct. 10, 2017.
`Catrina et al.. Mechanisms I eading from Systemic Auto Immunity
`to Joint-specific Disease in Rheumatoid Arthritis, Natural Review,
`Rheumatology, 13(2), 79-86. Dec. 2016.
`Neogi et al., The Eflect of Alendr‘onate on Progression of Spinal
`Osteophytes and Disc-space Narrowing, Annals Rheumatic Dis-
`eases, 67, 1427-30, Feb. 2008.
`Almaresmni et al., Imaging Studies in Freund’s Complete Adjuvant
`Model of Regional Polyarthritis, a Model Suitable for the Study of
`Pain Mechanisms,
`in the Rat, Arthritis & Rheumatism, 63(6),
`1573-81, Jun. 2011.
`Chillingworth & Donaldson, Characterisation of a Freund’s com-
`plete adjuvant-induced model of chronic arthritis in nice,
`J.
`Neurosci.Mcthods,128(1-2), 45-52, Sep. 2003.
`Rollins. Chapter 38: Preformulation, in Remington’s Pharm. Sci.,
`700-20, 2000 (Lirmner et al. eds., 20th ed. 2000).
`Malinowski, Chapter 53: Bioavailability & Bioequivalence Testing,
`in Remington’s Pharm. Sci., 995-1004, 2000 (Limmer et al. eds.,
`20th ed. 2000).
`in Remington’s
`Rollins. Chapter 59: Clinical Pharmacokinetics,
`Pharm. Sci., 1145—55, 2000 (Limmer et al. eds, 20th ed. 2000).
`Yamada, et al., Gastric pII Profile and Its Control in Fasting Beagle
`Dogs, Chem. Pharm. Bull, 37(9), 2539-2541, Sep. 1989.
`Lui, ct al., Comparison of Gastrointestinal pH in Dogs and Humans:
`Implications on the Use of the Beagle Dog as a Model for Oral
`Absorption in Humans. J. Pharm. Sci.. 75(3). 271-74. Mar. 1986.
`Buckland-Wright et al., A 2 yr Longitudinal Radiographic Study
`Examining the Eflect of a Bisphosphonate ('Risedronate) upon
`Subchondral Bone Loss in Osteoarthritic Knee Patients, Rheumatol-
`ogy, 46, 257-64, Jul 2007.
`McQueen et al.. Zoledronic Acid Does not Reduce MRI
`ErosiveProgression in PsA but may Suppress Bone Oedema: the
`Zoledronic A